Premenopausal women presenting with acute coronary syndrome (ACS) are a unique and often underrecognized patient population. Although they are traditionally considered at lower cardiovascular risk ...
Introduction Ischaemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide and poses an ...
New data show Lp(a) may only raise heart risk if paired with belly fat or inflammation. A simple waist-to-hip ratio could ...
Objectives Female sex and anticitrullinated protein antibodies (ACPA) are associated with higher disease activity in ...
The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...
Cardiovascular diseases (CVDs) are the leading cause of death around the world, indicates the Centers for Disease Control and ...
A step-by-step, evidence-informed framework for interpreting high coronary calcium CT results, refining cardiovascular risk, and implementing integrative pr ...
Total net revenue of $15.2 million Adjusted EBITDA1 of $ (0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) ...
Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel ...
Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA (gepirone) extended-r ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results